Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Comparison of Ethylenediaminetetraacetic Acid-Treated Desmoglein Elisa and Conventional Desmoglein Elisa in the Evaluation of Pemphigus Vulgaris in Remission Publisher Pubmed



Daneshpazhooh M1 ; Mahmoudi H1 ; Balighi K1 ; Teimourpour A1, 2 ; Khodashenas Z1 ; Ghiasi M1 ; Khosravi H1, 3 ; Chamsdavatchi C1
Authors

Source: Journal of the American Academy of Dermatology Published:2018


Abstract

[No abstract available]
Related Docs
View other Related Docs
1. Short-Term Clinical and Serological Follow-Up With Conventional and Conformational Anti-Desmoglein Antibodies in Treatment-Naive and Previously Treated Patients With Pemphigus Vulgaris After Receiving Rituximab, International Journal of Women's Dermatology (2019)
2. Current Status and Prospects for the Diagnosis of Pemphigus Vulgaris, Expert Review of Clinical Immunology (2021)
3. Estimated Cut-Off Values for Pemphigus Severity Classification According to Pemphigus Disease Area Index (Pdai), Autoimmune Bullous Skin Disorder Intensity Score (Absis), and Anti-Desmoglein 1 Autoantibodies, BMC Dermatology (2020)
Experts (# of related papers)
View all Related Experts
Maryam Daneshpajooh (7)
Hamid Reza Mahmoodi (6)
Other Related Docs
4. Rituximab in Practice: Clinical Evaluation of Patients With Pemphigus After Rituximab Administration, Dermatologic Therapy (2021)
5. Investigating Expression Pattern of Eight Immune-Related Genes in Pemphigus Patients Compared With the Healthy Controls and After Rituximab Therapy: Potential Roles of Ctla4 and Fcgr3a Genes Expression in Outcomes of Rituximab Therapy, Dermatologic Therapy (2020)
6. Immunologic Prediction of Relapse in Patients With Pemphigus Vulgaris (Pv) in Clinical Remission, Journal of the American Academy of Dermatology (2016)
7. Factors Associated With the Healing Time of Pemphigus Vulgaris Oral Lesions: A Prospective Study, Oral Diseases (2023)